KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.88
+5.03%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- -$1.16
- Revenue estimate
- $33.5M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$2.32
- EPS estimate
- -$1.37
- Revenue actual
- $33.4M
- Revenue estimate
- $32.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -11.5%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $5.00
- PT range
- $3.00 – $7.00
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$1.37 | -$2.32 | Miss -69.34% | $33.4M |
| May 14, 2026 | -$1.45 | -$1.24 | Beat 14.48% | $35.1M |
| Feb 12, 2026 | -$2.26 | -$2.23 | Beat 1.33% | $34.1M |
| Feb 19, 2025 | -$3.90 | -$3.60 | Beat 7.69% | $30.5M |
| Feb 29, 2024 | -$4.35 | -$5.40 | Miss -24.14% | $33.7M |
| Nov 2, 2023 | -$4.20 | -$4.50 | Miss -7.14% | $36.0M |
| Aug 2, 2023 | -$5.10 | -$4.35 | Beat 14.71% | $37.6M |
| May 4, 2023 | -$5.10 | -$4.50 | Beat 11.76% | $38.7M |
| Feb 15, 2023 | -$5.10 | -$6.45 | Miss -26.47% | $33.6M |
| Nov 3, 2022 | -$8.40 | -$6.75 | Beat 19.64% | $36.1M |
| Aug 4, 2022 | -$9.45 | -$9.30 | Beat 1.59% | $39.7M |
| May 5, 2022 | -$9.45 | -$7.95 | Beat 15.87% | $47.7M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026